These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 36483011)
1. DLL3 regulates Notch signaling in small cell lung cancer. Kim JW; Ko JH; Sage J iScience; 2022 Dec; 25(12):105603. PubMed ID: 36483011 [TBL] [Abstract][Full Text] [Related]
2. Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer. Zhang H; Yang Y; Li X; Yuan X; Chu Q Biomed Pharmacother; 2023 Mar; 159():114248. PubMed ID: 36645960 [TBL] [Abstract][Full Text] [Related]
3. Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC. Li W; Ye L; Huang Y; Zhou F; Wu C; Wu F; He Y; Li X; Wang H; Xiong A; Gao G; Wang L; Su C; Ren S; Chen X; Zhou C Lung Cancer; 2022 May; 167():25-33. PubMed ID: 35381444 [TBL] [Abstract][Full Text] [Related]
4. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors. Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005 [TBL] [Abstract][Full Text] [Related]
5. Delta-like ligand 3 in small cell lung cancer: Potential mechanism and treatment progress. Yang W; Wang W; Li Z; Wu J; Huang X; Li J; Zhang X; Ye X Crit Rev Oncol Hematol; 2023 Nov; 191():104136. PubMed ID: 37716517 [TBL] [Abstract][Full Text] [Related]
6. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail. Furuta M; Kikuchi H; Shoji T; Takashima Y; Kikuchi E; Kikuchi J; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J Cancer Sci; 2019 May; 110(5):1599-1608. PubMed ID: 30874360 [TBL] [Abstract][Full Text] [Related]
8. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702). Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H; Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386 [TBL] [Abstract][Full Text] [Related]
9. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures. Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352 [TBL] [Abstract][Full Text] [Related]
10. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of Delta-Like Protein 3 in a Consecutive Series of Surgically Resected Lung Neuroendocrine Neoplasms. Alì G; Di Stefano I; Poma AM; Ricci S; Proietti A; Davini F; Lucchi M; Melfi F; Fontanini G Front Oncol; 2021; 11():729765. PubMed ID: 34568063 [TBL] [Abstract][Full Text] [Related]
12. TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer. Nie F; Chen Y; Hu Y; Huang P; Shi X; Cai J; Qiu M; Wang E; Lu K; Sun M Immunology; 2024 Jul; 172(3):362-374. PubMed ID: 38469682 [TBL] [Abstract][Full Text] [Related]
14. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges. Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324 [TBL] [Abstract][Full Text] [Related]
15. The predictive value of delta-like3 and serum NSE in evaluating chemotherapy response and prognosis in patients with advanced small cell lung carcinoma: An observational study. Zhu C; Huang J; Jin X; Zhang C; Zhu C; Lv M; Chen S; Du X; Feng G Medicine (Baltimore); 2024 Jun; 103(23):e38487. PubMed ID: 38847733 [TBL] [Abstract][Full Text] [Related]
16. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Yao J; Bergsland E; Aggarwal R; Aparicio A; Beltran H; Crabtree JS; Hann CL; Ibrahim T; Byers LA; Sasano H; Umejiego J; Pavel M Oncologist; 2022 Nov; 27(11):940-951. PubMed ID: 35983951 [TBL] [Abstract][Full Text] [Related]
17. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Saunders LR; Bankovich AJ; Anderson WC; Aujay MA; Bheddah S; Black K; Desai R; Escarpe PA; Hampl J; Laysang A; Liu D; Lopez-Molina J; Milton M; Park A; Pysz MA; Shao H; Slingerland B; Torgov M; Williams SA; Foord O; Howard P; Jassem J; Badzio A; Czapiewski P; Harpole DH; Dowlati A; Massion PP; Travis WD; Pietanza MC; Poirier JT; Rudin CM; Stull RA; Dylla SJ Sci Transl Med; 2015 Aug; 7(302):302ra136. PubMed ID: 26311731 [TBL] [Abstract][Full Text] [Related]
18. Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer. Bylsma LC; Pundole X; Ju CH; Hooda N; Movva N; Elkhouly E; Bebb G; Fryzek J; Martinez P; Balasubramanian A; Dingemans AC Target Oncol; 2023 Nov; 18(6):821-835. PubMed ID: 37930513 [TBL] [Abstract][Full Text] [Related]
19. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer. Huang J; Cao D; Sha J; Zhu X; Han S Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917 [TBL] [Abstract][Full Text] [Related]
20. DLL3: an emerging target in small cell lung cancer. Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]